Duvelisib R enantiomer

• CAT Number: I001051
• CAS Number: 1261590-48-0
• Molecular Formula: C22H17ClN6O
• Molecular Weight: 416.86
• Purity: ≥95%
• Target: PI3K
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 8-chloro-2-phenyl-3-[(1R)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
• InChI: InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m1/s1
• InChIKey: SJVQHLPISAIATJ-CYBMUJFWSA-N
• SMILES: C[C@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

Duvelisib R-enantiomer(CAT: I001051) is the stereoisomer of Duvelisib, a known PI3K inhibitor. This compound serves as a critical tool for studying the role of stereochemistry in PI3K signaling pathways and its impact on biological activity. While Duvelisib primarily targets PI3K-δ and PI3K-γ isoforms, the R-enantiomer allows researchers to evaluate enantioselective interactions and off-target effects. It is particularly valuable in drug discovery, enabling precise analysis of stereoisomer-specific pharmacodynamics and pharmacokinetics. With high purity and reliable consistency, Duvelisib R-enantiomer supports advanced research in oncology, immunology, and metabolic diseases.